- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04765592
Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)
April 28, 2024 updated by: Hangzhou Endonom Medtech Co., Ltd.
A prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for true/false aortic arch aneurysms and ulcers involving aortic arch .
(GIANT Study)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective ,multiple center study about the safety and efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System, it is expected to complete the implantation of 80 patients in 23 centers within 12 months, and interim follow-up was conducted before discharge, 30 days after surgery, 6 months after surgery and 12 months after surgery, long-term follow-up will be performed at 24 months postoperatively, 36 months postoperatively, 48 months postoperatively and 60 months postoperatively.
Study Type
Interventional
Enrollment (Actual)
88
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Chinese PLA General Hospital
-
Beijing, China
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
-
Beijing, China
- Peking University People's Hospital
-
Beijing, China
- Beijing Anzhen Hospital, Capital Medical University
-
Changsha, China
- Xiangya Hospital of Central South University
-
Chengdu, China
- West China Hospital of Sichuan University
-
Guangzhou, China
- The First Affiliated Hospital ,Sun Yat-sen University
-
Hangzhou, China
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
Hangzhou, China
- First Affiliated Hospital of Zhejiang University School of Medicine
-
Harbin, China
- The Second Affiliated Hospital of Harbin Medical University
-
Jinan, China
- Shandong Provincial Hospital
-
Kunming, China
- The First People's Hospital of Yunnan Province
-
Nanjing, China
- Nanjing First Hospital
-
Nanjing, China
- Nanjing Drum Tower Hospital
-
Qingdao, China
- The Affiliated Hospital of Qingdao University
-
Shanghai, China
- Zhongshan Hospital, Fudan University
-
Shanghai, China
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai, China
- The Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
-
Shenyang, China
- The First Affiliated Hospital of China Medical University
-
Suzhou, China
- The First Affiliated Hospital of Soochow University
-
Tianjin, China
- Tianjin Medical University General Hospital
-
Xian, China
- The First Affiliated Hospital of PLA Air Force Military Medical University
-
Zhengzhou, China
- First Affiliated Hospital of Zhengzhou University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients aged 18 to 80 years old;
- Diagnosed with aortic arch lesions requiring intervention, including true aortic arch aneurysms, pseudo-aortic arch aneurysms, and ulcers involving the aortic arch;
Showing a suitable vascular condition, including:
- Ascending aorta length greater than 50 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery).
- Ascending aorta diameter ≥ 24 mm and ≤ 48 mm;
- Proximal anchoring zone length ≥ 30 mm;
- Innominate artery diameter ≤ 24 mm and ≥ 7 mm, length ≥ 20 mm;
- Left common carotid artery or left subclavian artery diameter ≤ 24 mm and ≥ 7 mm, length ≥ 20 mm;
- Suitable arterial access for endovascular interventional treatment;
- Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol.
- Evaluated by at least two vascular surgeons or cardiac surgeons as high surgical risk patients or deemed to have significant surgical contraindications.
Exclusion Criteria:
- Experienced systemic infection during past three months;
- Neck surgery was performed within 3 months;
- Previous endovascular interventional treatment involving the aortic arch was performed;
- Infectious aortic disease、Takayasu arteritis,Marfan syndrome (or other connective tissue diseases );
- Severe stenosis, calcification, thrombosis, or tortuosity of the carotid or subclavian artery;
- Heart transplant;
- Suffered MI or stroke during past three months;
- Class IV heart function (NYHA classification);
- Active peptic ulcers or upper gastrointestinal bleeding occurring within the previous three months;
- Hematological abnormality, defined as follows: Leukopenia (WBC < 3 × 109/L), acute anemia (Hb < 90 g/L); thrombocytopenia (PLT count < 50 × 109/L), history of bleeding or coagulopathy;
- Renal insufficiency, creatinine > 265 umol/L (or 3.0mg/dL) and/or end-stage renal disease requiring renal dialysis, as determined by an investigator after a thorough analysis;
- Pregnant or breastfeeding;
- Allergies to contrast agents;
- Life expectancy of less than 12 months;
- Participating in another drug or device research;
- Any other disease or abnormality that the investigators believe may hinder endovascular interventional treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WeFlow-Arch Modeler Embedded Branch Stent Graft System
Participants will be treated with WeFlow-Arch Modeler Embedded Branch Stent Graft System
|
The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of all-cause mortality and major stroke within 12 months after surgery
Time Frame: 12 months after surgery
|
All-cause mortality includes cardiac mortality, non-cardiac mortality, and mortality from unknown causes.
Severe stroke is defined as a modified Rankin score (mRS) ≥ 2 at 90 days following stroke onset.
|
12 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of immediate technical success following surgery
Time Frame: immediately after the surgery
|
Immediate technical success is defined as successful delivery of the aortic and branching stent graft conveyors to their predetermined positions, accurate positioning and successful deployment of the stent, safe removal of the delivery device outside the body, and the absence of Type I and III endoleaks per imaging studies conducted at the end of the procedure with all branching stents patency.
|
immediately after the surgery
|
Rate of aortic aneurysm progression under control
Time Frame: 12 months after operation
|
Aortic aneurysm progression under control is defined as maximum increase in the diameter of the aortic aneurysm was ≤ 5 mm when compared with preoperative aortic aneurysm as of a 12-month postoperative CTA review
|
12 months after operation
|
Incidence of Type I or Type III endoleak
Time Frame: immediately after the surgery, 1 month, 6 months, 12 months after the surgery
|
Incidence of Type I or Type III endoleak before discharge, 1 month, 6 months, 12 months after operation.
Intraoperative endoleaks subject to adjuvant treatment are not recorded.
Endoleaks occurring after the completion of the procedure followed by one or more endoleaks occurring in the same subject at different follow-up stages that were not treated are counted as a single instance.
|
immediately after the surgery, 1 month, 6 months, 12 months after the surgery
|
Incidence of aortic arch stent graft displacement
Time Frame: 1 month, 6 months, 12 months after operation
|
CTA examination will be performed at 1 month, 6 months, and 12 months post operation to determine if the stent has migrated, and evaluations will be recorded for both the main and branch stents.
Displacement is defined as a nodal aortic or branching stent graft displacement of more than 10 mm from pre-discharge levels.
|
1 month, 6 months, 12 months after operation
|
Postoperative branch vessel patency rate
Time Frame: 1 month, 6 months, 12 months after operation
|
CTA examinations will be performed at 1 month, 6 months, and 12 months post operation to evaluate branch vessel reconstruction and assess for occlusion, stenosis, or in-stent thrombosis.
|
1 month, 6 months, 12 months after operation
|
Incidence of surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention
Time Frame: 30 days, 6 months, and 12 months after operation
|
Incidence of surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention 30 days, 6 months, and 12 months after operation.Whether or not the patient experienced surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention will be determined.
|
30 days, 6 months, and 12 months after operation
|
Rate of major adverse events
Time Frame: 30 days post operation
|
Refers to all-cause mortality, myocardial infarction, ischemic stroke, or respiratory failure occurring within 30 days after surgery.
More specifically, myocardial infarction refers to a drastic reduction or complete interruption of the coronary blood supply due to coronary artery disease, resulting in severe and prolonged acute ischemia of the corresponding myocardium, leading to necrosis of cardiomyocytes.
Ischemic stroke refers to the result of necrosis of brain tissue caused by narrowing or occlusion of the arteries supplying blood to the brain or insufficient blood supply to the brain.
Respiratory failure is defined as a state resulting in significantly prolonged intubation, tracheotomy, deterioration of lung function, or other fatal outcomes.
|
30 days post operation
|
Rate of aortic aneurysm-related mortality
Time Frame: 12 months post operation
|
Refers to mortality caused by a ruptured aortic aneurysm or endovascular interventional treatment.
|
12 months post operation
|
Incidence of severe adverse events
Time Frame: 30 days, 6 months, and 12 months after operation
|
Refers to an event that occurs during the clinical trial that results in mortality or serious deterioration in patient health, including a fatal illness or injury, a permanent defect in body structure or body function, or an event that requires medical or surgical intervention to avoid one or more permanent defects in body structure or body function.
|
30 days, 6 months, and 12 months after operation
|
Incidence of device-related adverse events
Time Frame: 30 days, 6 months, and 12 months after operation
|
Device-related adverse events refer to an adverse medical event related to the use of a device that occurs during the clinical trial.
However, a distinction should be made with respect to normal postoperative stress response, such as fever and chest and back discomfort, which, in the judgment of the investigator, need not be recorded as an adverse event.
Recording of device-related adverse events will be applicable for conditions that are deemed by the investigator to be definitely related, possibly related, or of indeterminate relationship, to the test device.
|
30 days, 6 months, and 12 months after operation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 7, 2021
Primary Completion (Estimated)
February 5, 2025
Study Completion (Estimated)
February 5, 2029
Study Registration Dates
First Submitted
February 4, 2021
First Submitted That Met QC Criteria
February 19, 2021
First Posted (Actual)
February 21, 2021
Study Record Updates
Last Update Posted (Actual)
April 30, 2024
Last Update Submitted That Met QC Criteria
April 28, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WEIQIANG202001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data will be shared for scientific purposes after the completion of the clinical trial.
However, patients' electronic records and any CTA files are outside the scope of our data sharing policy.
Researchers wanting to request data can submit a detailed application to the investigators.
Data will be released depending on the scientific quality of the submitted request.
IPD Sharing Time Frame
It is expected that data will be obtained after study completion for at least one year.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Arch Aneurysm
-
University Hospital MuensterRecruitingAortic Arch Aneurysm | Aortic Arch | Dissection of Aortic Arch | Triple BranchGermany
-
Baptist Health South FloridaWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch AneurysmUnited States
-
Gustavo OderichWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Aortic Arch DissectionUnited States
-
Fuji Systems CorporationAvaniaActive, not recruitingAortic Aneurysm | Aortic Dissection | Aortic Arch Aneurysm | Aortic Arch; Aneurysm, DissectingGermany, Netherlands
-
Hangzhou Endonom Medtech Co., Ltd.Recruiting
-
Endospan Ltd.CompletedAortic Arch AneurysmSwitzerland, Italy, New Zealand
-
Centre Hospitalier Universitaire de Saint EtienneCompletedAortic Arch AneurysmFrance, Netherlands
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
Darren Schneider, M.D.RecruitingEndovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent GraftsAortic Aneurysm, Thoracic | Aortic Aneurysm, Thoracoabdominal | Aortic Dissection, ThoracoabdominalUnited States
-
Cook Research IncorporatedRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch Aneurysm | Complex Abdominal Aortic Aneurysm | Chronic Aortic DissectionDenmark, France, Germany
Clinical Trials on WeFlow-Arch Modeler Embedded Branch Stent Graft System
-
Hangzhou Endonom Medtech Co., Ltd.Recruiting
-
Hangzhou Endonom Medtech Co., Ltd.CompletedAortic Arch; Aneurysm, DissectingChina
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingAortic Aneurysm and DissectionChina
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingJuxtarenal Abdominal Aortic AneurysmChina
-
Hangzhou Endonom Medtech Co., Ltd.Active, not recruiting
-
Hangzhou Endonom Medtech Co., Ltd.UnknownJuxta Renal Abdominal Aortic Aneurysm Without RuptureChina
-
Andres SchanzerRecruitingMarfan Syndrome | Ehlers-Danlos Syndrome | Aortic Arch Aneurysm | Complex Aortic Aneurysms | Juxtarenal Aneurysms | Loeys-Dietz Syndrome | Thoracoabdominal Aneurysms | Pararenal AneurysmsUnited States
-
China National Center for Cardiovascular DiseasesActive, not recruitingAortic Dissection | Aortic Intramural Hematoma | Aneurysm, Aortic Arch | Aortic Pseudoaneurysm | Aortic Ulcer, PenetratingChina
-
Lifetech Scientific (Shenzhen) Co., Ltd.Recruiting
-
Cook Group IncorporatedTerminatedAorto-iliac Aneurysms | Iliac AneurysmsHong Kong, United Kingdom, Germany